Adam J. Gadzinski, MD, MS

home / authors / adam-j-gadzinski-md-ms

Articles

Adam J. Gadzinski, MD, MS

Adam J. Gadzinski, MD, MS, on Up-and-Coming Research for Urologic Oncology

Adam J. Gadzinski, MD, MS
January 7th 2021

The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.

Telehealth

Adam J. Gadzinski, MD, MS, on Next Steps for Assessing the Impact of Telemedicine on Patient-Reported Outcomes

Adam J. Gadzinski, MD, MS
January 3rd 2021

An expert in urologic oncology seeks to answer further questions regarding the use of telemedicine for this patient population.

Adam J. Gadzinski, MD, MS

Adam J. Gadzinski, MD, MS, on the Limitations of a Study Assessing the Impact of Telemedicine on Patient-Reported Outcomes

Adam J. Gadzinski, MD, MS
December 28th 2020

Study results revealed the impact of a rurally focused telemedicine program on patient outcomes.

Adam J. Gadzinski, MD, MS

Adam J. Gadzinski, MD, MS, on Study Results Assessing the Impact of Telemedicine on Patient-Reported Outcomes

Adam J. Gadzinski, MD, MS
December 21st 2020

The study was designed to determine the impact of a rurally focused telemedicine program on patient outcomes.

Adam J. Gadzinski, MD, MS

Adam J. Gadzinksi, MD, MS, on the Impact of Telemedicine on Patient-Reported Outcomes

Adam J. Gadzinski, MD, MS
December 9th 2020

The study assessed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center.

Adam J. Gadzinski, MD, MS

Adam J. Gadzinski, MD, MS, on the Design of a Study Assessing Impact of Telemedicine on Patient-Reported Outcomes

Adam J. Gadzinski, MD, MS
December 7th 2020

The study sought to determine the impact of a rurally focused telemedicine program on patient outcomes.

Adam J. Gadzinski, MD, MS

Adam J. Gadzinski, MD, MS, on the Research Coming Out of SUO This Year

Adam J. Gadzinski, MD, MS
December 5th 2020

Gadzinski spoke about the most exciting aspect of the research coming out of the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
A 23-Year-Old Male With Right Leg Pain
Published: April 26th 2018 | Updated: July 24th 2025
A 23-Year-Old Male With Right Leg Pain